PPARα agonists, such as the fibrate class of drugs, are effective in the treatment of dyslipidemia, where they raise HDL and reduce serum triglycerides, properties that decrease incidence of atherosclerosis and reduce risk for the development of cardiovascular disorders [19]–[21]. The gene discussed is PPARA; the disease is cardiovascular disorder.